eligibility_summary
Eligible: adults (≥18), any sex, with histologically confirmed DLBCL, PMBCL, tFL, or follicular lymphoma receiving inpatient axi-cel CAR-T at MD Anderson, able to understand and sign consent. Exclude: prior CAR-T received, unwilling/unable to comply (incl. pupillometer), or unacceptable risk per investigator.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
A pilot observational study in lymphoma patients receiving axicabtagene ciloleucel (axi-cel) CD19 CAR-T. Interventions: NeurOptics NPi-300 Pupillometer (device) that noninvasively quantifies the pupillary light reflex and computes the Neurological Pupil index (NPi) to detect changes associated with neurotoxicity. Drug context: axi-cel is an autologous, genetically engineered T-cell therapy expressing a chimeric antigen receptor that targets CD19 on B cells to drive cytotoxic killing. Cells/pathways targeted: CD19+ B lymphocytes by CAR-T, autonomic/brainstem pupillary pathways (optic/oculomotor nerve–mediated light reflex) as physiologic markers of immune effector cell-associated neurotoxicity (ICANS).